Jeffrey L. Bennett, MD, PhD - University of Colorado Denver
Jeffrey L. Bennett, MD, PhD - University of Colorado Denver
Jeffrey L. Bennett, MD, PhD - University of Colorado Denver
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NMO Prevention: Mitoxantrone<br />
intercalates DNA and inhibits topoisomerase<br />
II, limits B and T cell proliferation<br />
Dosage: 3 monthly cycles: 12 mg/m 2 ;<br />
maintenance <strong>of</strong> 6-12 mg/m 2 every 3 months<br />
Benefits: ARR reduced to 0.7; reduced EDSS<br />
Adverse events: cardiotoxicity, leukemia,<br />
hepatotoxicity, leukopenia<br />
Weinstock-Guttman et al. (2006). Arch Neurol 63:957.<br />
Kim et al. (2010). Arch Neurol 68:473.
Change language